PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 30.80
+0.02 (0.07%)
Sep 1, 2026, 4:00 PM EDT
SHE:301230 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,391 | 4,108 | 3,510 | 3,853 | 4,107 | - | |
Market Cap Growth | 3.44% | 17.04% | -8.90% | -6.18% | - | - |
Enterprise Value | 5,253 | 3,981 | 3,336 | 3,484 | 4,132 | - |
Last Close Price | 30.15 | 22.82 | 19.27 | 20.49 | 21.66 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 146.69 | 119.80 | 205.47 | 102.42 | 61.13 | - |
Forward PE | 89.08 | 74.67 | 52.62 | 30.60 | - | - |
PS Ratio | 7.70 | 5.97 | 6.45 | 7.87 | 8.57 | - |
PB Ratio | 5.32 | 4.09 | 3.40 | 3.45 | 3.69 | - |
P/TBV Ratio | 5.37 | 4.13 | 3.43 | 3.48 | 3.72 | - |
P/FCF Ratio | 52.63 | 44.56 | - | - | - | - |
P/OCF Ratio | 32.07 | 30.32 | 43.41 | 184.72 | 41.36 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 7.50 | 5.78 | 6.13 | 7.12 | 8.63 | - |
EV/EBITDA Ratio | 73.50 | 78.33 | 193.24 | 73.49 | 53.94 | - |
EV/EBIT Ratio | 172.88 | 176.56 | - | 130.77 | 68.58 | - |
EV/FCF Ratio | 51.28 | 43.18 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.14 | 0.17 | 0.18 | 0.19 | 0.09 | 0.31 |
Debt / EBITDA Ratio | 2.02 | 2.24 | 4.52 | 3.32 | 1.13 | 0.98 |
Debt / FCF Ratio | 1.41 | 1.79 | - | - | - | 8.33 |
Net Debt / Equity Ratio | -0.14 | -0.15 | -0.15 | -0.31 | -0.61 | -0.01 |
Net Debt / EBITDA Ratio | -2.30 | -2.90 | -9.22 | -7.25 | -8.88 | -0.05 |
Net Debt / FCF Ratio | -1.34 | -1.60 | 5.58 | 1.51 | 27.58 | -0.37 |
Asset Turnover | 0.53 | 0.52 | 0.39 | 0.35 | 0.52 | 0.99 |
Inventory Turnover | 7.38 | 7.15 | 6.35 | 6.23 | 6.22 | 5.16 |
Quick Ratio | 2.67 | 2.71 | 3.55 | 3.34 | 8.61 | 1.60 |
Current Ratio | 3.37 | 3.38 | 4.42 | 3.82 | 9.28 | 2.15 |
Return on Equity (ROE) | 3.69% | 3.37% | 1.59% | 3.37% | 9.19% | 24.06% |
Return on Assets (ROA) | 1.43% | 1.07% | -0.40% | 1.19% | 4.05% | 11.97% |
Return on Invested Capital (ROIC) | 3.42% | 2.61% | -1.08% | 4.42% | 14.30% | 28.64% |
Return on Capital Employed (ROCE) | 2.70% | 2.00% | -0.70% | 2.10% | 5.00% | 20.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.71% | 0.83% | 0.49% | 0.98% | 1.64% | - |
FCF Yield | 1.90% | 2.24% | -0.81% | -5.90% | -0.60% | - |
Dividend Yield | 0.76% | 1.25% | 1.72% | 0.95% | 0.98% | - |
Payout Ratio | 180.57% | 157.59% | 288.43% | 103.18% | 1.17% | 1.06% |
Buyback Yield / Dilution | -3.40% | -0.38% | -2.19% | -26.05% | -5.66% | -1.58% |
Total Shareholder Return | -2.64% | 0.87% | -0.47% | -25.10% | -4.68% | -1.58% |